The Qualio Blog
Insights on product development, quality management, and regulatory compliance for teams building life-saving products.
Every quality management system on your shortlist will pass your evaluation
Most quality management software evaluations cannot separate the field, because they measure what every vendor already does. Three questions that sort it.
The compliance tax you are already paying
Compliance cost is real and rarely measured. Put a number on what you spend today across audit prep, QA capacity, documents, and consultants.
The Sidekick Becomes a Coworker: What a Quality Leader Learned About Trusting AI With Compliance
One quality leader explains why AI needs to become a coworker, not just a sidekick, before audit prep stops being a last-minute scramble.
The EU Expands Its "Well-Established Technologies" List Again
The EU expanded its MDR "well-established technologies" list again, growing it roughly fivefold. See which device categories now qualify for reduced requirements.
MHRA's 2026 Devices Reform: What Changes and When
MHRA's draft Medical Devices (Amendment) Regulations 2026 reshape GB's pre-market framework, adoption expected December 2026. See what changes and when.
FDA's Risk-Based Inspection Shift: What It Actually Rewards
FDA's revised PAI guide takes effect August 2026, favoring risk-based reviews over onsite inspections by default. See what the shift actually rewards.
ISO 14971 in the Age of AI: What ISO/TS 24971-2:2026 Adds
ISO/TS 24971-2:2026 guides ML risk management under ISO 14971. See what the new companion standard covers, and what it means for your risk file.
What the FDA's AI Device Software Guidance Signals for Your Traceability
FDA's draft AI-enabled device guidance demands dataset provenance and post-market monitoring across the TPLC. See what it means for your traceability now.
From Algorithm to Aisle: What Naritas CEO Nora Keldy Teaches Us About Building AI-Native Life Sciences Companies
From algorithm to aisle: Naritas CEO Nora Keldy on why AI-native biotech companies can't separate scientific ambition from quality infrastructure — and what that means for how you build.
Why the FSP Model Is Having Its Moment (and What It Means for Clinical Trial Operations)
Why are more biopharma sponsors turning to functional service providers? Dr. Les Enterline of PPD breaks down the FSP model, the rise of mixed-model outsourcing, and what it really takes to flex clinical trial resources without sacrificing quality or control.